“Enfortumab vedotin plus pembrolizumab has the potential to become a platinum-free option for cisplatin-ineligible locally advanced and metastatic urothelial cancer patients in the first-line setting," said Christopher J. Hoimes, DO, hematologist/oncologist at University Hospitals, assistant professor at ÐÇ¿Õ´«Ã½ School of Medicine, and member of the Case CCC's GU Malignancies program, at the 2019 European Society for Medical Oncology (ESMO) Congress at the end of September.
Article Date
October 04, 2019